COVID-19 Vaccine Updates: VITT Has High Mortality, Myocarditis Is Benign Short-Term
Recipients of AstraZeneca’s vaccine hospitalized with vaccine-induced immune thrombocytopenia and thrombosis (VITT) had overall mortality of 22%, NEJM study finds. JAMA reports 15 children who had myocarditis following Pfizer/BioNTech vaccine were mildly affected. Efficacy of Moderna vaccine in adolescents and durability of Pfizer vaccine in cancer treatment recipients is also reported.
You may also be interested in...
Rare Or Common Events? COVID Vaccine Trials In Children Boost Safety Databases, Triggering Fears Of Heart Events
US FDA seems to want Moderna and Pfizer to study their mRNA vaccines in 3,000 people ages five to 11, suggesting the rate of myocarditis in younger children may be higher than in older teens. Such a finding, and even the hunt for it, could push back any COVID-19 vaccine authorization for this population.
US FDA will rapidly update fact sheets with information on myocarditis/pericarditis occurring primarily in young men and adolescent males following the second dose, agency's Doran Fink tells the CDC’s Advisory Committee on Immunization Practices, which said benefit-risk of the Pfizer/BioNTech and Moderna vaccines remains favorable.
Number of deaths and ICU admissions that may have been prevented without the pause is ‘striking,’ CDC advisory committee member says; ACIP votes to reaffirm use of J&J’s vaccine in persons 18 and older based on positive risk-benefit analysis and reports of only nine additional cases of TTS.